Compare · GH vs HUM
GH vs HUM
Side-by-side comparison of Guardant Health Inc. (GH) and Humana Inc. (HUM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GH and HUM operate in Medical Specialities (Health Care), so they compete in similar markets.
- HUM is the larger of the two at $45.00B, about 1.9x GH ($23.66B).
- Over the past year, GH is up 193.0% and HUM is up 49.6% - GH leads by 143.4 points.
- GH has been more active in the news (16 items in the past 4 weeks vs 9 for HUM).
- Both have 25 recent analyst ratings on file.
- Company
- Guardant Health Inc.
- Humana Inc.
- Price
- $176.40+0.10%
- $380.23+1.58%
- Market cap
- $23.66B
- $45.00B
- 1M return
- +6.99%
- -2.22%
- 1Y return
- +192.97%
- +49.57%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 16
- 9
- Recent ratings
- 25
- 25
Guardant Health Inc.
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing tests from its LUNAR program for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; LUNAR-2 test for the early detection of cancer in asymptomatic individuals eligible for cancer screening; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for residual disease and recurrence monitoring; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical trial referral, and liquid biopsy testing development and support services to biopharmaceutical companies and medical institutions. Daiichi Sankyo has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.
Humana Inc.
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, predictive modeling and informatics services, and clinical care services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2020, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was incorporated in 1964 and is headquartered in Louisville, Kentucky.
Latest GH
- Director Mignone Roberto converted options into 264 shares, increasing direct ownership by 3% to 10,274 units (SEC Form 4)
- Director Hidalgo Medina Manuel converted options into 232 shares, increasing direct ownership by 5% to 5,020 units (SEC Form 4)
- Chief Technology Officer Chudova Darya sold $1,377,364 worth of shares (7,738 units at $178.00), decreasing direct ownership by 10% to 70,635 units (SEC Form 4)
- Director Azar Alex M Ii sold $144,550 worth of shares (826 units at $175.00), decreasing direct ownership by 50% to 825 units (SEC Form 4)
- Director Krognes Steve E. sold $1,172,886 worth of shares (6,674 units at $175.74), decreasing direct ownership by 46% to 7,906 units (SEC Form 4)
- Director Tariq Musa converted options into 249 shares and sold $20,300 worth of shares (116 units at $175.00), increasing direct ownership by 1% to 11,449 units (SEC Form 4)
- SEC Form 144 filed by Guardant Health Inc.
- Director Azar Alex M Ii converted options into 1,651 shares (SEC Form 4)
- Chief Information Officer Kalia Kumud sold $632,193 worth of shares (4,000 units at $158.05), decreasing direct ownership by 9% to 39,794 units (SEC Form 4)
- Guardant Health’s Shield Blood Test Covered by EviCore by Evernorth for Colorectal Cancer Screening
Latest HUM
- New Humana research finds association between pharmacy care coordination services and improved health outcomes for cancer patients
- Humana Community Day 2026 Generates 2.2 Million Meals and Community Investments Nationwide
- New Study Links Integrated Specialty Pharmacy Care to Faster Access and Lower Costs
- Chief Medical Officer Nundy Shantanu was granted 2,549 units of Humana Common (SEC Form 4)
- Humana Earns 2026 Great Place To Work Certification™ and PEOPLE Companies That Care® Recognition
- Humana Board Declares Payment of Quarterly Dividend to Stockholders
- Humana Foundation Names 2026 Scholarship Recipients
- Humana Inc. filed SEC Form 8-K: Regulation FD Disclosure
- New insider Nundy Shantanu claimed no ownership of stock in the company (SEC Form 3)
- Humana Names Dr. Shantanu Nundy as Chief Medical Officer